Effect of agomelatine treatment on C-reactive protein levels in patients with major depressive disorder: an exploratory study in “real-world,” everyday clinical practice

Evaluation of C-Reactive Protein and Total Serum Cholesterol in Adult Patients with Bipolar Disorder

(2017) D. De Berardis et al.   INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY

Sustained efficacy of agomelatine 10 mg, 25 mg, and 25–50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months

(2016) Sidney H. Kennedy et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Influence of sleep deprivation and circadian misalignment on cortisol, inflammatory markers, and cytokine balance

(2015) Kenneth P. Wright et al.   BRAIN BEHAVIOR AND IMMUNITY

Effect of Circadian Rhythm on Clinical and Pathophysiological Conditions and Inflammation

(2015) Takako Kizaki et al.   CRITICAL REVIEWS IN IMMUNOLOGY

Inflammatory Biomarkers as Differential Predictors of Antidepressant Response

(2015) Kenji Hashimoto   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

An Inflammatory Biomarker as a Differential Predictor of Outcome of Depression Treatment With Escitalopram and Nortriptyline

(2014) Rudolf Uher et al.   AMERICAN JOURNAL OF PSYCHIATRY

A phase-specific neuroimmune model of clinical depression

(2014) H.A. Eyre et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Cytokine and adipokine alterations in patients with schizophrenia treated with clozapine

(2014) Jari-Pekka Klemettilä et al.   PSYCHIATRY RESEARCH

The mechanism, efficacy, and tolerability profile of agomelatine

(2013) Sarah E MacIsaac et al.   EXPERT OPINION ON PHARMACOTHERAPY

The Melatonergic System in Mood and Anxiety Disorders and the Role of Agomelatine: Implications for Clinical Practice

(2013) Domenico De Berardis et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance

(2012) Matteo Martino et al.   Current Neuropharmacology

Onset, time course and trajectories of improvement with antidepressants

(2012) Raymond W. Lam   EUROPEAN NEUROPSYCHOPHARMACOLOGY

The Emerging Role of Melatonin Agonists in the Treatment of Major Depression: Focus on Agomelatine

(2011) Domenico De Berardis et al.   CNS & Neurological Disorders-Drug Targets

Novel melatonin-based therapies: potential advances in the treatment of major depression

(2011) Ian B Hickie et al.   LANCET

Role of C-Reactive Protein in Contributing to Increased Cardiovascular Risk in Metabolic Syndrome

(2010) Sridevi Devaraj et al.   Current Atherosclerosis Reports

A Systematic, Updated Review on the Antidepressant Agomelatine Focusing on its Melatonergic Modulation

(2010) Michele Fornaro et al.   Current Neuropharmacology

Response and remission criteria in major depression – A validation of current practice

(2010) Michael Riedel et al.   JOURNAL OF PSYCHIATRIC RESEARCH

Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression

(2009) Andrew H. Miller et al.   BIOLOGICAL PSYCHIATRY

A Meta-Analysis of Cytokines in Major Depression

(2009) Yekta Dowlati et al.   BIOLOGICAL PSYCHIATRY